Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study

Chihiro Takahashi, Yuko Kaneko, Yutaka Okano, Hiroaki Taguchi, Hisaji Oshima, Keisuke Izumi, Kunihiro Yamaoka, Tsutomu Takeuchi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA). Methods: 79 MTX-naïve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed. Results: Dose escalation of MTX resulted in increased MTX-PG concentrations and a decrease in the mean Disease Activity Score in 28 joints (DAS28). A significant association was observed between total MTX-PG concentrations and ΔDAS28 at week 12 (β=-0.013, p=0.003) and at week 24 (β=-0.014, p=0.003). The maximum MTX-PG levels were significantly higher in patients presenting with elevated transaminases (≥100 IU/L) than in those without (146 vs 106 nmol/L, p=0.009). Receiver operating characteristic curve analysis revealed that a total MTX-PG concentrations of 83 nmol/L at week 12 was the threshold for a DAS28 improvement of ≥1.2 at week 24, and 105 nmol/L was the threshold for transaminases of ≥50 IU/L and 131 nmol/L for transaminases of ≥100 IU/L. MTX-PG concentrations were strongly influenced by body mass index and a serum albumin level. Conclusions: MTX-PG concentrations are a useful biomarker in MTX therapy, in terms of efficacy and safety.

Original languageEnglish
Article numbere000363
JournalRMD Open
Volume3
Issue number1
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Methotrexate
Rheumatoid Arthritis
Erythrocytes
Prospective Studies
Transaminases
Joints
Safety
methotrexate polyglutamate
Serum Albumin
ROC Curve
Liquid Chromatography
Body Mass Index
Cohort Studies
Biomarkers

Keywords

  • Methotrexate
  • Rheumatoid Arthritis
  • Treatment

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis : A 76-week prospective study. / Takahashi, Chihiro; Kaneko, Yuko; Okano, Yutaka; Taguchi, Hiroaki; Oshima, Hisaji; Izumi, Keisuke; Yamaoka, Kunihiro; Takeuchi, Tsutomu.

In: RMD Open, Vol. 3, No. 1, e000363, 01.01.2017.

Research output: Contribution to journalArticle

@article{aad240da117842a2822989c761e2d19f,
title = "Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: A 76-week prospective study",
abstract = "Objective: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA). Methods: 79 MTX-na{\"i}ve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed. Results: Dose escalation of MTX resulted in increased MTX-PG concentrations and a decrease in the mean Disease Activity Score in 28 joints (DAS28). A significant association was observed between total MTX-PG concentrations and ΔDAS28 at week 12 (β=-0.013, p=0.003) and at week 24 (β=-0.014, p=0.003). The maximum MTX-PG levels were significantly higher in patients presenting with elevated transaminases (≥100 IU/L) than in those without (146 vs 106 nmol/L, p=0.009). Receiver operating characteristic curve analysis revealed that a total MTX-PG concentrations of 83 nmol/L at week 12 was the threshold for a DAS28 improvement of ≥1.2 at week 24, and 105 nmol/L was the threshold for transaminases of ≥50 IU/L and 131 nmol/L for transaminases of ≥100 IU/L. MTX-PG concentrations were strongly influenced by body mass index and a serum albumin level. Conclusions: MTX-PG concentrations are a useful biomarker in MTX therapy, in terms of efficacy and safety.",
keywords = "Methotrexate, Rheumatoid Arthritis, Treatment",
author = "Chihiro Takahashi and Yuko Kaneko and Yutaka Okano and Hiroaki Taguchi and Hisaji Oshima and Keisuke Izumi and Kunihiro Yamaoka and Tsutomu Takeuchi",
year = "2017",
month = "1",
day = "1",
doi = "10.1136/rmdopen-2016-000363",
language = "English",
volume = "3",
journal = "RMD Open",
issn = "2056-5933",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Association of erythrocyte methotrexate-polyglutamate levels with the efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis

T2 - A 76-week prospective study

AU - Takahashi, Chihiro

AU - Kaneko, Yuko

AU - Okano, Yutaka

AU - Taguchi, Hiroaki

AU - Oshima, Hisaji

AU - Izumi, Keisuke

AU - Yamaoka, Kunihiro

AU - Takeuchi, Tsutomu

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA). Methods: 79 MTX-naïve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed. Results: Dose escalation of MTX resulted in increased MTX-PG concentrations and a decrease in the mean Disease Activity Score in 28 joints (DAS28). A significant association was observed between total MTX-PG concentrations and ΔDAS28 at week 12 (β=-0.013, p=0.003) and at week 24 (β=-0.014, p=0.003). The maximum MTX-PG levels were significantly higher in patients presenting with elevated transaminases (≥100 IU/L) than in those without (146 vs 106 nmol/L, p=0.009). Receiver operating characteristic curve analysis revealed that a total MTX-PG concentrations of 83 nmol/L at week 12 was the threshold for a DAS28 improvement of ≥1.2 at week 24, and 105 nmol/L was the threshold for transaminases of ≥50 IU/L and 131 nmol/L for transaminases of ≥100 IU/L. MTX-PG concentrations were strongly influenced by body mass index and a serum albumin level. Conclusions: MTX-PG concentrations are a useful biomarker in MTX therapy, in terms of efficacy and safety.

AB - Objective: To assess the utility of erythrocyte methotrexate-polyglutamate (MTX-PG) concentrations in determining the safety and efficacy of MTX in patients with rheumatoid arthritis (RA). Methods: 79 MTX-naïve patients with RA were enrolled in this prospective 76-week cohort study. MTX was initiated, and a predefined dose-escalation protocol was followed. Erythrocyte MTX-PG concentrations were measured using liquid chromatography. The associations of MTX-PG concentrations with disease activity and adverse events were analysed. Results: Dose escalation of MTX resulted in increased MTX-PG concentrations and a decrease in the mean Disease Activity Score in 28 joints (DAS28). A significant association was observed between total MTX-PG concentrations and ΔDAS28 at week 12 (β=-0.013, p=0.003) and at week 24 (β=-0.014, p=0.003). The maximum MTX-PG levels were significantly higher in patients presenting with elevated transaminases (≥100 IU/L) than in those without (146 vs 106 nmol/L, p=0.009). Receiver operating characteristic curve analysis revealed that a total MTX-PG concentrations of 83 nmol/L at week 12 was the threshold for a DAS28 improvement of ≥1.2 at week 24, and 105 nmol/L was the threshold for transaminases of ≥50 IU/L and 131 nmol/L for transaminases of ≥100 IU/L. MTX-PG concentrations were strongly influenced by body mass index and a serum albumin level. Conclusions: MTX-PG concentrations are a useful biomarker in MTX therapy, in terms of efficacy and safety.

KW - Methotrexate

KW - Rheumatoid Arthritis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85009152862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009152862&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2016-000363

DO - 10.1136/rmdopen-2016-000363

M3 - Article

AN - SCOPUS:85009152862

VL - 3

JO - RMD Open

JF - RMD Open

SN - 2056-5933

IS - 1

M1 - e000363

ER -